Jiangsu Aierkang Biomedical Technology

Jiangsu Aierkang Biomedical Technology is a clinical-stage biotechnology company based in Nanjing, China, specializing in the development of pluripotent stem cell-derived therapies for ophthalmic diseases. The company's primary focus is on treating degenerative retinal conditions, such as age-related macular degeneration (AMD), through the transplantation of human embryonic stem cell-derived retinal pigment epithelial (RPE) cells. Aierkang's lead program has received IND approval and is undergoing clinical evaluation to assess safety and efficacy in restoring vision. By leveraging its proprietary cell differentiation and purification platforms, the company aims to provide regenerative medicine solutions for previously untreatable blinding diseases.